Company Overview - Sido Medical Co., Ltd. is an innovative pharmaceutical company focused on oncology and chronic disease treatment, with a vision to "help cancer patients live longer and better" [2] - The company has a product line of 12 innovative drugs with differentiated clinical value, 8 of which are in clinical development or commercialization stages [2] - The first subcutaneous PD-L1 single-domain antibody drug, Envida, has been approved for sale by the National Medical Products Administration [2] - The company utilizes its proprietary mRNA research platform and tumor genomic big data AI analysis platform to develop a series of mRNA products [2] - Sido Medical has established capabilities from drug discovery to clinical research, regulatory submission, and commercialization [2] Financial Performance - As of December 31, 2024, Sido Medical reported total revenue of 446 million yuan, a year-on-year decrease of 29.81% [1] - The net profit attributable to the parent company was -183 million yuan, an increase of 65.19% year-on-year [1] - The gross profit margin stood at 91.79%, and the debt-to-asset ratio was 42.14% [1] Market Performance - As of July 30, the Hang Seng Index fell by 1.36%, closing at 25,176.93 points [1] - Sido Medical's stock price closed at 7.18 HKD per share, up 12.54%, with a trading volume of 3.025 million shares and a turnover of 21.9126 million HKD, showing a volatility of 23.2% [1] - Over the past month, Sido Medical's stock has increased by 59.1%, and year-to-date, it has risen by 107.14%, outperforming the Hang Seng Index by 27.24% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 2.73 times, with a median of 6.48 times [1] - Sido Medical's P/E ratio is -8.35 times, ranking 129th in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as: - Qianjing Pharmaceutical (00858.HK): 1.37 times - Genscript Biotech (01548.HK): 1.76 times - Dongrui Pharmaceutical (02348.HK): 3.5 times - Jilin Changlong Pharmaceutical (08049.HK): 6.14 times - Dajiankang International (02211.HK): 6.83 times [1]

Company Overview - Sido Medical Co., Ltd. is an innovative pharmaceutical company focused on oncology and chronic disease treatment, with a vision to "help cancer patients live longer and better" [2] - The company has a product line of 12 innovative drugs with differentiated clinical value, 8 of which are in clinical development or commercialization stages [2] - The first subcutaneous PD-L1 monoclonal antibody, Envida, has been approved for sale by the National Medical Products Administration [2] - The company utilizes its proprietary mRNA research platform and tumor genomic big data AI analysis platform to develop a series of mRNA products [2] - Sido Medical has established capabilities across drug discovery, preclinical research, clinical development, regulatory submission, and commercialization [2] Financial Performance - As of December 31, 2024, Sido Medical reported total revenue of 446 million yuan, a year-on-year decrease of 29.81% [1] - The company recorded a net profit attributable to shareholders of -183 million yuan, an increase of 65.19% year-on-year [1] - The gross profit margin stands at 91.79%, with a debt-to-asset ratio of 42.14% [1] Market Position and Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 1.96 times, with a median of 6.18 times [1] - Sido Medical's P/E ratio is -5.69 times, ranking 132nd in the industry [1] - Comparatively, other companies in the industry have P/E ratios such as: Qingdao Haier Biomedical (0.86), Kingsray Biotechnology (1.43), Dongrui Pharmaceutical (3.06), and Jilin Changlong Pharmaceutical (6.00) [1]